1	HOUSE BILL 76
2	57TH LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2025
3	INTRODUCED BY
4	Elizabeth "Liz" Thomson
5	
6	
7	
8	
9	
10	AN ACT
11	RELATING TO NEWBORN INFANT HEALTH; ADDING ECHOCARDIOGRAMS AND
12	ELECTROCARDIOGRAMS TO THE REQUIRED TESTS FOR NEWBORN INFANTS
13	WHO ARE AT HIGHER RISK OF CONGENITAL HEART DISEASE.
14	
15	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:
16	SECTION 1. Section 24-1-6 NMSA 1978 (being Laws 1973,
17	Chapter 359, Section 6, as amended) is amended to read:
18	"24-1-6. TESTS REQUIRED FOR NEWBORN INFANTS
19	A. The department shall adopt screening tests for
20	the detection of congenital diseases that shall be given to
21	every newborn infant, except that, after being informed of the
22	reasons for the tests, the parents or guardians of the newborn
23	child may waive the requirements for the tests in writing. The
24	screening tests shall include at a minimum:
25	 3-methylcrotonyl-CoA deficiency;
	.228836.2

underscored material = new
[bracketed material] = delete

	1		(2) 3-OH 3-CH3 glutaric aciduria;
	2		(3) argininosuccinic acidemia;
	3		(4) mitochondrial acetoacetyl-CoA thiolase
	4	deficiency;	
	5		(5) biotinidase deficiency;
	6		(6) carnitine uptake defect;
	7		(7) citrullinemia;
	8		(8) congenital adrenal hyperplasia;
	9		(9) congenital hypothyroidism;
	10		(10) cystic fibrosis;
	11		(11) galactosemia;
	12		(12) glutaric acidemia type I;
	13		(13) Hb S/beta-thalassemia;
	14		(14) hearing deficiency;
	15		(15) homocystinuria;
	16		(16) isovaleric acidemia;
	17		(17) long-chain L-3-OH acyl-CoA dehydrogenase
	18	deficiency;	
•	19		(18) maple syrup urine disease;
	20		(19) medium chain acyl-CoA dehydrogenase
	21	deficiency;	
	22		(20) methylmalonic acidemia;
	23		(21) multiple carboxylase deficiency;
	24		(22) phenylketonuria;
	25		(23) proponic acidemia;
		.228836.2	- 2 -

[bracketed material] = delete <u>underscored material = new</u>

1	(24) sickle cell anemia;
2	(25) trifunctional protein deficiency;
3	(26) tyrosinemia type I;
4	(27) very long-chain acyl-CoA dehydrogenase
5	deficiency; and
6	(28) critical congenital heart disease:
7	<u>(a)</u> by means of a test performed using a
8	pulse oximeter before the newborn infant is discharged from the
9	hospital or birthing facility where the newborn infant was
10	born. For the purposes of this [paragraph] <u>subparagraph</u> ,
11	"pulse oximeter" means a device that measures the oxygen
12	saturation of arterial blood; <u>and</u>
13	(b) by means of an echocardiogram and
14	electrocardiogram if the newborn infant has a familial history
15	of congenital heart disease or if either of the newborn
16	infant's biological parents report that they: 1) have ever
17	fainted, passed out or had an unexplained seizure suddenly and
18	without warning, especially during exercise; 2) have ever had
19	exercise-related chest pain or shortness of breath; 3) are
20	related to someone who has died of a heart problem or an
21	unexpected sudden death before the age of fifty, including a
22	death from drowning, an unexplained car accident or sudden
23	infant death syndrome; or 4) are related to someone with heart-
24	related issues or anyone younger than fifty years old who has a
25	pacemaker or implantable defibrillator. If a facility lacks
	.228836.2

underscored material = new
[bracketed material] = delete

- 3 -

-			
1	the equipment or staff to perform these tests, the facility		
2	shall provide to the newborn infant's parents a referral to		
3	receive an echocardiogram and electrocardiogram upon discharge.		
4	B. Upon the later of either January 1, 2011 or when		
5	the secretary finds that these screening tests are reasonably		
6	available, the department shall adopt screening tests for the		
7	detection of the following genetic diseases that shall be given		
8	to every newborn infant; except that, after being informed of		
9	the reasons for the tests, the parents or guardians of the		
10	newborn child may waive the requirements of the tests in		
11	writing. The screening tests shall include:		
12	(1) acid maltase deficiency or glycogen		
13	storage disease type II;		
14	(2) globoid cell leukodystrophy;		
15	(3) Gaucher's disease;		
16	(4) Niemann-Pick disease; and		
17	(5) Fabry disease.		
18	C. In determining which other congenital diseases		
19	to screen for, the secretary shall consider the recommendations		
20	of the New Mexico pediatric society [of] <u>and</u> the American		
21	academy of pediatrics.		
22	D. The department shall institute and carry on such		
23	laboratory services or may contract with another agency or		
24	entity to provide such services as are necessary to detect the		
25	presence of congenital diseases.		
	.228836.2		
	- 4 -		

[bracketed material] = delete <u>underscored material = new</u>

1	E. The department shall, as necessary, carry on an
2	educational program among physicians, hospitals, public health
3	nurses and the public concerning congenital diseases.
4	F. The department shall require that all hospitals
5	or institutions having facilities for childbirth perform or
6	have performed screening tests for congenital diseases on all
7	newborn infants except if the parents or guardians of a child
8	object to the tests in writing.
9	G. For the purposes of this section:
10	(1) "echocardiogram" means a test that uses
11	ultrasound to detect heart defects, assess heart function and
12	evaluate congenital anomalies; and
13	(2) "electrocardiogram" means a test that
14	measures the heart's electrical activity to aid with the
15	diagnosis of arrhythmias or other heart issues."
16	- 5 -
17	
18	
19	
20	
21	
22	
23	
24	
25	
	.228836.2

underscored material = new
[bracketed material] = delete